Brent Campbell, DO
Family Medicine · Hixson, TNNPI 1285841254
Payments from drug & device makers
Across 407 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$630
- AstraZeneca$503
- AbbVie$477
- Abbott$374
- Pfizer$373
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,442100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $1,139 |
| Boehringer Ingelheim | 40 | $630 |
| AstraZeneca(2 entities) | 34 | $503 |
| AbbVie(2 entities) | 32 | $477 |
| Abbott | 19 | $374 |
| Pfizer | 25 | $373 |
| Lilly USA, LLC | 26 | $348 |
| Amgen | 19 | $299 |
| Merck | 17 | $244 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $194 |
| Amarin Pharma, Inc. | 9 | $180 |
| Bayer | 10 | $175 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $155 |
| GSK | 8 | $129 |
| Xeris Pharmaceuticals, Inc. | 6 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $111 |
| Johnson & Johnson | 6 | $94 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Eisai Inc. | 6 | $88 |
| Jazz Pharmaceuticals Inc. | 4 | $87 |
| Esperion Therapeutics, Inc. | 4 | $77 |
| Astellas Pharma US Inc | 4 | $75 |
| Sanofi-aventis U.S. LLC | 5 | $75 |
| Arbor Pharmaceuticals, Inc. | 4 | $57 |
| Neos Therapeutics, LP | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Novartis | 2 | $35 |
| Nevro Corp. | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Pacira Therapeutics, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
How this compares
$6,451 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $178,235 |
| JardianceEmpagliflozin | 145 | $129,887 |
| FarxigaDapagliflozin Propanediol | 117 | $85,492 |
| EliquisApixaban | 84 | $80,457 |
| XareltoRivaroxaban | 55 | $48,230 |
| RybelsusSemaglutide | 15 | $24,772 |
| MyrbetriqMirabegron | 38 | $23,471 |
| JanuviaSitagliptin Phosphate | 28 | $19,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $18,874 |
| EntrestoSacubitril/Valsartan | 30 | $16,430 |
| MounjaroTirzepatide | 14 | $14,103 |
| Tiotropium Bromide | 12 | $12,597 |
| ElmironPentosan Polysulfate Sodium | 12 | $12,003 |
| Omeprazole | 512 | $8,572 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,139 | $203,007168 claims |
| Boehringer IngelheimJardiance | $630 | $129,887145 claims |
| AstraZenecaFarxiga, Symbicort | $503 | $90,563133 claims |
| PfizerEliquis | $373 | $80,45784 claims |
| Johnson & JohnsonXarelto | $94 | $48,23055 claims |
| MerckJanuvia, Belsomra | $244 | $24,36340 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $23,47138 claims |
| GSKTrelegy Ellipta | $129 | $18,87429 claims |
| NovartisEntresto | $35 | $16,43030 claims |
| Lilly USA, LLCMounjaro | $348 | $14,10314 claims |
| AbbVieSynthroid | $477 | $1,97539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Hixson
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.